"Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)", briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

  • Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
  • Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
  • Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time

The report comprises three sections -

Executive Summary

  • Contains analysis of key market events that have occurred during the previous month and which have impacted the NASH landscape.

Landscape Updates

  • ’Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product’s lifecycle management initiatives.
  • ’Market Entry’ & ’Direction of Travel’ positioning analysis for pipeline therapies.

Pipeline Landscape

  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2020.


  • Current early stage RA pipeline & candidate ’Watch List’.
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.


  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • ’Market Entry’ & ’Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons To Buy

  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.